Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced <scp>NSCLC</scp> Who Received Pretreatment With <scp>EGFR</scp> ‐ <scp>TKIs</scp> ( <scp>ML41256</scp> ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial
Year: 2025
Type: article
Language: en
Topic: Lung Cancer Treatments and Mutations
Authors and affiliations:
raw_author_name: Wenfeng Fang
raw_affiliation_strings: Department of Medical Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine  Guangzhou China
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
raw_author_name: Jian Fang
raw_affiliation_strings: Second Department of Thoracic Oncology Beijing Cancer Hospital  Beijing China
Second Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China
raw_author_name: Panwen Tian
raw_affiliation_strings: Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital Sichuan University  Chengdu China
Lung Cancer Center/Lung Cancer Institute, West China Hospital Sichuan University  Chengdu Sichuan China
Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China
raw_author_name: Yun Fan
raw_affiliation_strings: Department of Medical Oncology Zhejiang Cancer Hospital  Hangzhou China
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China
raw_author_name: Qitao Yu
raw_affiliation_strings: Department of Respiratory Oncology Guangxi Medical University Affiliated Tumor Hospital  Nanning China
Department of Respiratory Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China
raw_author_name: Xiaochun Zhang
raw_affiliation_strings: Cancer Precision Medical Center, The Affiliated Hospital of Qingdao University  Qingdao China
Cancer Precision Medical Center, The Affiliated Hospital of Qingdao University, Qingdao, China
raw_author_name: Zhehai Wang
raw_affiliation_strings: Respiratory Medical Oncology Ward II Shandong Cancer Hospital  Jinan China
Respiratory Medical Oncology Ward II, Shandong Cancer Hospital, Jinan, China
raw_author_name: Xiaoyuan Liu
raw_affiliation_strings: Medical Affairs Shanghai Roche Pharmaceuticals Ltd.  Shanghai China
Medical Affairs, Shanghai Roche Pharmaceuticals Ltd., Shanghai, China
raw_author_name: Yanjun Shi
raw_affiliation_strings: Medical Affairs Shanghai Roche Pharmaceuticals Ltd.  Shanghai China
Medical Affairs, Shanghai Roche Pharmaceuticals Ltd., Shanghai, China
raw_author_name: Li Zhang
raw_affiliation_strings: Department of Medical Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine  Guangzhou China
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China